Xentria Inc.

Address: 2032 North Clybourn Avenue Suite 100

Sponsor Overview

assignment

Specializations

Pulmonary sarcoidosis and systemic inflammatory disease

Clinical research in pulmonary sarcoidosis with or without extrapulmonary manifestations is a major focus, with attention to respiratory involvement and broader inflammatory burden.

Immune-mediated granulomatous disease
Corticosteroid-sparing therapy
Long-term safety and tolerability

Work in this area centers on treatment options for patients with persistent disease activity and associated organ involvement.

Osteoporosis and bone health

The sponsor supports research in postmenopausal osteoporosis, with emphasis on bone preservation and comparative biologic performance in bone mineral density outcomes.

Bone remodeling
Postmenopausal bone loss
Biologic similarity in osteoporosis care

This therapeutic area reflects interest in skeletal fragility and therapies used to reduce fracture-related risk.

Reproductive medicine and functional female infertility

Research also extends to functional female infertility, indicating involvement in reproductive endocrinology and treatments relevant to ovulatory function and fertility support.

Female infertility
Fertility treatment
Reproductive hormone support

These studies align with clinical interest in conditions affecting conception and reproductive capacity.

Healthy volunteer pharmacology

Trials in healthy volunteers support evaluation of pharmacokinetics, pharmacodynamics, and immunogenicity for biologic candidates and comparability studies.

Pharmacokinetic similarity
Safety and tolerability
Biologic characterization

This area underpins development work across immune, endocrine, and bone-related therapeutic programs.

Sponsored Trials

Trial Name	Country	Status
A Phase I Pharmacokinetic and Safety Study Comparing KM04 to Recombinant Human Follicle-Stimulating Hormone in Healthy Adult Female Volunteers	Poland	Not Yet Recruiting
A seamless, phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations	Czechia Denmark Italy Poland Spain	Recruiting
Comparative Study of Efficacy, Pharmacokinetics, and Safety of Denosumab (MAB-22) Versus EU-Sourced Denosumab in Postmenopausal Osteoporosis	Bulgaria Czechia Poland	Not Recruiting
Evaluation of Long-term Safety and Efficacy of XTMAB-16 in Pulmonary Sarcoidosis with or without Extrapulmonary Manifestations	Czechia Denmark Italy Poland Spain	Recruiting
Pharmacokinetic Comparison of MAB-22 and Prolia® (EU and US) in Healthy Male Volunteers: A Randomized, Double-Blind, Controlled, Parallel-Group Study	Hungary The Netherlands	Not Recruiting
Phase 1b/2 Multiple Ascending Dose Study of Intravenous XTMAB-16 in Patients with Pulmonary Sarcoidosis (with or without Extrapulmonary Manifestations)	Czechia Denmark Greece Italy Poland Spain	Not Yet Recruiting